Stockreport

Zevra Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Updates

Zevra Therapeutics, Inc.  (ZVRA) 
PDF FDA approval of MIPLYFFA™ and product launch cap third quarter filled with multiple commercial and clinical development milestones Zevra received ra [Read more]